Foundation Medicine, a Cambridge, MA-based personalized cancer medicine firm, said today it will conduct a pilot collaboration with the drug giant Novartis. The companies will work together to optimize Foundation’s cancer genome panel to fit Novartis’s needs, according to Foundation. Based on the pilot, Foundation and Novartis will determine whether to commercialize the test. The firms did not disclose financial details of the arrangement.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
